Evaluating changes to the gut microbiome in patients with cirrhosis identified potential problems and reduced the likelihood the patient would be readmitted, according to a study led by Jasmohan Bajaj, MD, a professor of medicine at Virginia Commonwealth University, that was published in GastroHep. The study used tests ranging from $250 to $650 and found that the more expensive tests resulted in the most overall cost savings.
Checking gut microbiome in cirrhosis may prevent readmission
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.